The Clinical Measurement Ontology (CMO), Measurement Methods Ontology (MMO), and Experimental Condition Ontology (XCO) are currently being developed at the Rat Genome Database. For more information about these vocabularies please see Shimoyama et al. Three ontologies to define phenotype measurement data. Front Genet. 2012;3:87. Epub 2012 May 28 or contact us (https://rgd.mcw.edu/rgdweb/contact/contactus.html).
Term:
organ tumorous lesion incidence/prevalence measurement
A measurement in which the number of individuals in a study population that display one or more tumorous lesion(s) of a particular organ at a point in time or develop such lesions within a determined period of time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio. A tumorous lesion is a localized pathological change in structure of an organ or tissue due to injury or disease; especially one that is circumscribed and well defined, but which is or has the potential to become a tumor, that is, a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive. Tumorous lesions include tumors, preneoplastic lesions, and hyperplastic lesions composed of histologically normal cells.